Ryvu Therapeutics Presents Clinical and Translational Data of RVU120 at the 2022 ASH Annual Meeting
Current TAP Partner
Krakow, Poland – December 11, 2022 – Ryvu Therapeutics [WSE:RVU], a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, today announced new data demonstrating clinical and preclinical activity of its selective CDK8/19 inhibitor RVU120 at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition, which is being held on December 10 –13, 2022, in New Orleans, Louisiana.
Phase 1b Interim Efficacy and Safety Results on RVU120 as of a cut-off date of November 11, 2022:
- 16 relapsed/refractory (R/R) acute myeloid leukemia (AML) and 3 high-risk myelodysplastic syndrome (HR-MDS) patients with a median of 3 prior lines of therapy have been treated with RVU120 at doses between 75 and 110 mg;
- Clinical activity was demonstrated in 9 out of 16 evaluable patients, all of them with molecular markers preclinically predicted to respond to CDK8 inhibition;
- One AML patient achieved a complete response;
- 4 patients demonstrated blast reductions;
- 4 patients showed erythroid and/or platelet responses;
- RVU120 was generally well tolerated at all doses;
- Most frequent adverse events were nausea/vomiting, worsening of thrombocytopenia grade 3 to 4, and febrile neutropenia;
After the data cut-off for the poster, dose escalation has continued, and the 110 mg dose cohort has now been fully enrolled. In total, 22 patients have been enrolled in the study through December 7, 2022.